Figure S4 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects
Key Points
Key points are not available for this paper at this time.
Abstract
Figure S4 shows SpiD3 inhibits CLL chemotaxis and induces transcription of UPR genes.
Eiken et al. (Wed,) studied this question.
Figure S6 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects2024